Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL686488 | 0.88 | MEN1 (0.60) | MAPTNPC1RAB9AALDH1A1HTT | |
| SCHEMBL678581 | 0.83 | MAPT (0.65) | MAPTALDH1A1HTTMEN1POLB | |
| SCHEMBL4586417 | 0.80 | KCNMA1 (0.61) | MAPTALDH1A1HTTMEN1POLB | |
| SCHEMBL31155757 | 0.79 | CHRNB2 (0.69) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL2702303 | 0.76 | NPC1 (0.71) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL7821134 | 0.76 | MAPT (0.71) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL25063320 | 0.75 | MAPT (0.69) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL30981025 | 0.75 | NPC1 (1.00) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL7283173 | 0.75 | MAPT (0.69) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL30338901 | 0.75 | MAPT (0.69) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | MISSION PHARMACAL CO. (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | VIP, PDE3B, ADCY5 | MAPT 4872/4885SMN1; SMN2 4854/4885NPC1 2304/4885 |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | VIP, PDE3B, ADCY5 | MAPT 4872/4885SMN1; SMN2 4854/4885NPC1 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.